{
    "clinical_study": {
        "@rank": "38335", 
        "arm_group": {
            "arm_group_label": "valproic acid", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate if the addition of valproic acid to standard\n      platinum-based chemoradiation as definitive treatment of locally advanced Head and Neck\n      squamous cell carcinoma can improve treatment outcomes, such as response rate."
        }, 
        "brief_title": "Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma", 
        "condition": [
            "Head and Neck Cancer", 
            "Oral Cavity Cancer", 
            "Oropharyngeal Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms", 
                "Mouth Neoplasms", 
                "Oropharyngeal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Valproic acid is a known histone deacetylase inhibitor. In addition to activating apoptosis\n      pathways, cell differentiation and downregulating expression of growth factors, it also\n      promotes radiosensitization.\n\n      Most patients with Head and Neck squamous cell carcinoma are diagnosed with locally advanced\n      disease, in which long term disease control is still a challenge. The incorporation of\n      epigenetic regulation into standard treatment could improve results of definitive\n      platinum-based chemoradiation in such patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Unresectable Oropharyngeal or oral cavity squamous cell carcinoma\n\n          -  Candidate for definitive chemoradiation\n\n          -  No previous treatment\n\n          -  Measurable disease according to RECIST v 1.1\n\n          -  Previous neoplasia, other than Head and Neck, with more than five years without\n             evidence of disease; basocellular carcinoma of the skin and in situ cervical\n             dysplasia if resected\n\n          -  Age under 60 years\n\n          -  ECOG performance status 0-2\n\n          -  Ability of understanding and giving informed consent\n\n          -  Adequate renal and hepatic function\n\n          -  Adequate bone marrow function\n\n          -  Normal serum magnesium\n\n          -  Absence of QTc prolongation\n\n          -  Life expectancy of over 12 weeks\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Distant metastasis\n\n          -  Hypersensibility to valproic acid or other antiepileptic drugs\n\n          -  Valproic acid chronic use\n\n          -  Severe neurologic impairment\n\n          -  Uncontrolled comorbidity\n\n          -  Hypoalbuminemia\n\n          -  Known history of hepatitis B, C or HIV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695122", 
            "org_study_id": "327/11"
        }, 
        "intervention": {
            "arm_group_label": "valproic acid", 
            "intervention_name": "Valproic Acid", 
            "intervention_type": "Drug", 
            "other_name": "sodium valproate"
        }, 
        "intervention_browse": {
            "mesh_term": "Valproic Acid"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Head and Neck Cancer", 
            "Oropharyngeal cancer", 
            "Oral cavity cancer", 
            "Chemoradiation", 
            "valproic acid", 
            "histone deacetylase"
        ], 
        "lastchanged_date": "February 17, 2014", 
        "location": {
            "contact": {
                "email": "milena.mak@icesp.org.br", 
                "last_name": "Milena P Mak, MD", 
                "phone": "551138932000"
            }, 
            "contact_backup": {
                "last_name": "Gilberto Castro Jr, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Sao Paulo", 
                    "country": "Brazil", 
                    "state": "SP", 
                    "zip": "05409-011"
                }, 
                "name": "Instituto do Cancer do Estado de Sao Paulo"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "1", 
        "official_title": "Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma", 
        "other_outcome": {
            "measure": "Biomarkers assessment", 
            "safety_issue": "No"
        }, 
        "overall_official": {
            "affiliation": "Instituto do Cancer do Estado de Sao Paulo - University of Sao Paulo", 
            "last_name": "Milena P Mak, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "RECIST v 1.1", 
            "measure": "Response Rate", 
            "safety_issue": "No", 
            "time_frame": "Within 6 to 8 weeks after completion of chemoradiation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695122"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
            "investigator_full_name": "Milena Mak", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adverse reactions to study treatment", 
                "safety_issue": "Yes"
            }, 
            {
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Three years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Three Years"
            }, 
            {
                "measure": "Response rate comparison by p16 status", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No"
            }
        ], 
        "source": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Sao Paulo", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Instituto do Cancer do Estado de S\u00e3o Paulo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}